The National Drug Authority (NDA) has delivered a firm message to pharmaceutical companies to place patient safety above profit-making.
During a forum with industry stakeholders, NDA officials emphasized the critical need for ethical practices and regulatory compliance, reinforcing the responsibility of drug manufacturers to protect public health.
In its address, the NDA highlighted that pharmaceutical companies must ensure the safety and effectiveness of their products across the entire supply chain.
The safety of any drug on the market is the primary responsibility of the pharmaceutical company,” NDA officials stated, stressing the importance of proactive measures to monitor drug safety and quickly address potential risks.
The forum served as a reminder for companies to invest in robust tracking and monitoring systems.
This includes implementing dedicated pharmacovigilance teams to detect and report adverse drug reactions, as well as establishing strict quality control measures at every stage of production.
In addition to regulatory adherence, the NDA urged companies to uphold ethical values in their operations. “Patient safety must come first,” the NDA emphasized, noting that a strong commitment to safety not only builds public trust but also ensures Ugandans have access to dependable healthcare solutions.
With Uganda’s pharmaceutical industry rapidly expanding, the NDA is committed to strengthening oversight and fostering industry cooperation to maintain high safety standards.
The NDA warned that companies neglecting these responsibilities could face sanctions, underscoring that public health protection is a shared duty.
As Uganda’s pharmaceutical market continues to grow, the NDA remains focused on ensuring safe medication use, promoting industry best practices, and working with international regulators to align safety protocols.
